Advertisement

Topics

Aradigm secures SBIR grant to investigate use of Linhaliq and Lipoquin for PNTM treatment

19:00 EDT 15 Aug 2017 | Pharmaceutical Technology

Aradigm has secured a small business initiative research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH).

Original Article: Aradigm secures SBIR grant to investigate use of Linhaliq and Lipoquin for PNTM treatment

NEXT ARTICLE

More From BioPortfolio on "Aradigm secures SBIR grant to investigate use of Linhaliq and Lipoquin for PNTM treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...